
|Articles|February 15, 2004
Corneal implant applications expand to include keratoconus
Washington, DC-Micro-thin prescription inserts (Intacs, Addition Technology), which received FDA approval in the United States in 1999 for the treatment of mild myopia, are an alternative to tissue-ablating laser vision procedures and have a number of advantages.
Advertisement
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
First patient treated in ViaLase’s IDE trial
2
Formosa Pharmaceuticals and Rxilient sign licensing and commercialization agreement for APP13007
3
Iolyx Therapeutics and Laboratoires Théa enter into agreement over ILYX-002 for the treatment of OSD
4
FDA grants IDE approval to EyeYon Medical for its US clinical study of EndoArt
5















































.png)


